N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)-3,4-dihydro-2H-benzo[1,4]oxazine-8-carboxamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)-3,4-dihydro-2H-benzo[1,4]oxazine-8-carboxamide
• 英文别名: N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)-2,3-dihydro-1,4-benzoxazine-8-carboxamide
• 化学式: C₂₄H₂₄ClN₃O₂
• 分子量: 421.926
• InChiKey: VWXSTDUBMCMQTB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  54.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-(3-chloropyridin-2-yl)-3,4-dihydro-2H-benzo[1,4]oxazine-8-carboxylic acid 、 4-叔丁基苯胺 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 N-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)-3,4-dihydro-2H-benzo[1,4]oxazine-8-carboxamide
  参考文献：
  名称：

  CONDENSED BENZAMIDE COMPOUNDS AND INHIBITORS OF VANILLOID RECEPTOR SUBTYPE 1 (VR1) ACTIVITY

  摘要：

  提供一种对vanilloid受体亚型1（VR1）活性具有出色抑制作用的化合物，该化合物对于治疗与vanilloid受体亚型1（VR1）活性有关的疾病具有有效性，如疼痛、急性疼痛、慢性疼痛、神经病性疼痛、类风湿性关节炎疼痛、神经痛等，以及含有该化合物的药物组合物。该目标通过下面的式子所代表的缩合苯甲酰胺化合物（式子中的符号在说明书中定义了相同的含义）或其盐实现：

  公开号：

  US20060035882A1

文献信息

• FUSED BENZAMIDE COMPOUND AND VANILLOID RECEPTOR 1 (VR1) ACTIVITY INHIBITOR
  申请人：Japan Tobacco, Inc.

  公开号：EP1777225A1

  公开（公告）日：2007-04-25

  To provide a compound having an excellent inhibitory effect on vanilloid receptor subtype 1 (VR1) activity which is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, neuralgia, etc. and a pharmaceutical composition containing the compound. The object has been attained by a condensed benzamide compound represented by the following formula (the symbols in the formula have the same meanings defined in the specification) or its salt:

  提供一种对香草素受体亚型 1（VR1）活性具有优异抑制作用的化合物，该化合物可有效治疗与香草素受体亚型 1（VR1）活性有关的疾病，如疼痛、急性疼痛、慢性疼痛、神经病理性疼痛、类风湿性关节炎疼痛、神经痛等，以及含有该化合物的药物组合物。由下式（式中符号与说明书中定义的含义相同）代表的缩合苯甲酰胺化合物或其盐已达到上述目的：
• Condensed benzamide compounds as inhibitors of vanilloid receptor subtype 1 (VR1) activity
  申请人：Japan Tobacco, Inc.

  公开号：EP2314585A1

  公开（公告）日：2011-04-27

  To provide a compound having an excellent inhibitory effect on vanilloid receptor subtype 1 (VR1) activity which is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, neuralgia, etc. and a pharmaceutical composition containing the compound. The object has been attained by a condensed benzamide compound represented by the following formula (the symbols in the formula have the same meanings defined in the specification) or its salt:

  提供一种对香草素受体亚型 1（VR1）活性具有优异抑制作用的化合物，该化合物可有效治疗与香草素受体亚型 1（VR1）活性有关的疾病，如疼痛、急性疼痛、慢性疼痛、神经病理性疼痛、类风湿性关节炎疼痛、神经痛等，以及含有该化合物的药物组合物。由下式（式中符号与说明书中定义的含义相同）代表的缩合苯甲酰胺化合物或其盐已达到上述目的：
• MODULATORS AND METHODS FOR THE TREATMENT OF ROSACEA
  申请人：Aubert Jerome

  公开号：US20140031341A1

  公开（公告）日：2014-01-30

  An in vitro method of screening candidate compounds for the preventive or curative treatment of rosacea is described. The method can include determining the capacity of a compound to modulate the expression or activity of the Transient Receptor Potential (TRPs), as well as the use of modulators of the expression or activity of this transcription factor for the treatment of rosacea. The method can also include in vitro diagnosis or prognosis of this pathology.
• US8008292B2
  申请人：——

  公开号：US8008292B2

  公开（公告）日：2011-08-30
• CONDENSED BENZAMIDE COMPOUNDS AND INHIBITORS OF VANILLOID RECEPTOR SUBTYPE 1 (VR1) ACTIVITY
  申请人：Koga Yoshihisa

  公开号：US20060035882A1

  公开（公告）日：2006-02-16

  To provide a compound having an excellent inhibitory effect on vanilloid receptor subtype 1 (VR1) activity which is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, neuralgia, etc. and a pharmaceutical composition containing the compound. The object has been attained by a condensed benzamide compound represented by the following formula (the symbols in the formula have the same meanings defined in the specification) or its salt:

  提供一种对vanilloid受体亚型1（VR1）活性具有出色抑制作用的化合物，该化合物对于治疗与vanilloid受体亚型1（VR1）活性有关的疾病具有有效性，如疼痛、急性疼痛、慢性疼痛、神经病性疼痛、类风湿性关节炎疼痛、神经痛等，以及含有该化合物的药物组合物。该目标通过下面的式子所代表的缩合苯甲酰胺化合物（式子中的符号在说明书中定义了相同的含义）或其盐实现：